Pharma/fine chemicals roundup—12 November 2013
2:44 AM MST | November 12, 2013 | By DEEPTI RAMESH
CPhI 2013: Bullish mood at Frankfurt
CPhI, the largest annual trade fair for the global pharmaceutical and pharma ingredients industry and held recently at Frankfurt, attracted about 2,200 exhibitors and 34,000 visitors during its three days’ time. The mood of companies interviewed by CW was positive. “Pharmaceuticals have come through the worst of the trough, and the generic cliff we saw a few years ago has started to righten itself a bit,” says Will Downie, senior v.p./global business development and marketing at Catalent Pharma Solutions (Somerset, NJ). “That’s reflected in share prices, and the health-care sector overall is picking up again. Money is coming back into the system, the number of [initial public offerings] is increasing. There’s some optimism in the industry that we didn’t feel two or three years ago. I think we’re feeling pretty bullish about the industry,” he says.
Aurobindo Pharma reports rise in API sales
The active pharmaceutical ingredient (API) business of Aurobindo Pharma (Hyderabad, India) reports a 15.4% rise in sales in the second quarter, ended 30 September, compared with the year-ago quarter, to 7.18 billion Indian rupees ($113 million). For the six-month period ended 30 September, the API business reports a 12.9% rise in sales, compared with the year-ago period, to Rs13.65 billion. Earnings figures for the API business were not disclosed.
SAFC, UK firm form catalysis partnership
Sigma-Aldrich announced that its SAFC Commercial custom manufacturing services business unit has entered into a services agreement with CatScI Ltd., a Cardiff, UK-based catalysis company focused on maximizing yield, optimizing quality, reducing waste, and minimizing pharmaceuticals development costs. The partnership leverages CatScI’s expertise in catalyzed reactions and complex chemical processes and SAFC’s process development, scale-up, and manufacturing know-how. The importance of catalysis to the pharmaceutical industry has steadily grown over the past two decades due to increasing regulatory requirements such as policies on single-enantiomer drugs and environmental protection; the pressure to reduce drug development cost and time; and the continued discovery of new practical catalysts from both academia and industry, according to Sigma-Aldrich.
CPhI: India targets position as 'pharmacy of the world'
India has set ambitious growth targets for pharmaceutical exports, the India Brand Equity Foundation (IBEF; Gurgaon) and Pharmexcil (Hyderabad) announced recently at the CPhI trade show at Frankfurt. Exports of generics from India are growing at 24% annually, and that growth is forecast to continue for the next four years, according to IBEF and Pharmexcil. India ranks among the top six producers of pharmaceuticals globally, accounting for about 1.4% of the industry in value terms and about 10% by volume, according to IBEF and Pharmexcil. The country is the world's largest supplier of generics, and 8 of the top 25 generics companies are Indian. Pharmaceutical exports from India have grown at a compound annual growth rate of 68% over the last decade.
Evonik to provide drug formulation services for HPAPIs
Evonik Industries says it has broadened its capabilities in finished drug product formulation and clinical supply manufacturing and can now handle drug products containing highly potent active pharmaceutical ingredients (HPAPIs), at Darmstadt, Germany; and Birmingham, AL. “Active ingredients, functional excipients and tailored formulation development contribute to the ultimate success of advanced drugs and treatments. We are now in a position to offer our customers comprehensive services for the increasingly important class of HPAPIs,” says Thomas Riermeier, head of the pharma polymers & services product line at health care business line at Evonik. HPAPIs are substances that are pharmacologically active at very low concentrations. These active ingredients typically include certain hormones, peptides and cytostatic agents as well as new chemical entities that have not been completely characterized. “The number of companies in the world that work with HPAPIs is limited. Our small and large scale HPAPI production capacities in Hanau, Germany; and Lafayette, IN, together with our new capabilities for formulation development and clinical sample production in Darmstadt and Birmingham, make Evonik an ideal partner to the pharmaceutical industry in HPAPI manufacturing and formulation,” Riermeier says.
Codexis appoints v.p./strategic alliance, product development
Codexis (Redwood City, CA), a company that engineers enzymes for pharmaceutical, biofuel, and chemical productions, says it has appointed Greg Hughes as v.p./strategic alliance and product development, effective 28 October. Hughes spent the last 11 years in process chemistry at Merck & Co. with a primary focus in developing and implementing biocatalysis technology, Codexis says.
ScinoPharm and Genovate develop hepatitis B drug; ScinoPharm develops and manufactures the API
Active pharmaceutical ingredients (APIs) manufacturer ScinoPharm Taiwan (Shanhua, Taiwan) and Genovate Biotechnology (Taipei) say that they have jointly developed the highly potent oral generic drug Livepro (entecavir), representing a new generation of drugs for the treatment of hepatitis B. It is expected to be commercially available by the end of the year in Taiwan. Livepro has been jointly developed by Genovate and ScinoPharm with ScinoPharm being responsible for the development and manufacturing of the API for Livepro. Formulations were developed with the joint involvement of Genovate in order to enter the markets in Taiwan and China.
Shire to acquire ViroPharma for $4.2 billion
Shire (Dublin) and ViroPharma (Exton, PA), a rare disease biopharmaceutical company, say that they have entered into a merger agreement pursuant to which Shire will acquire all the outstanding shares of ViroPharma for $50/share in cash, for a total of about $4.2 billion. “The acquisition of ViroPharma will immediately benefit Shire and is entirely consistent with our clear strategic objective of strengthening our rare disease portfolio,” says Flemming Ornskov, CEO of Shire.
Connect with IHS Chemical Week
Our related sites